

Siteman Investment Program

Partner Prevention & Control-based

Interventional Clinical Trial Funding Mechanism

2026 Cycle 2 Request for Applications (RFA)

A. Overview

Available funding:

- Up to \$100,000 over 2 years (see section E for information on projects that cost >\$100,000). Priority will be given to projects with large accrual targets (>500) and involving a Siteman Cancer Network or BJC Collaborative partner site.

Timeline:

Date of announcement	July 23, 2026
REQUIRED Statement of Intent due by 4:00 PM CST	August 20, 2026
Full applications due by 4:00 pm CST	September 24, 2026
Project Start Date	January 2027

B. Purpose and Requirements

- To support new or ongoing prevention and control-based interventional trials involving at least one health system partner in SCC's catchment area (see Appendix A).
- Produce preliminary data to provide a basis for future Siteman Investment Program (SIP)/NCI/NIH applications (e.g., R01, R21) and/or,
- Accelerate dissemination and implementation research that moves evidence-based cancer practices into clinical and community settings and/or,
- Address health disparities in SCC's catchment area.
 - The full list of catchment area priorities based on community feedback and cancer burden includes the following: breast, prostate, lung, colorectal, HPV, tobacco cessation, and cancer survivorship.
 - For details on the cancer burden and social determinants of health for the catchment area, please consult the Community Dashboard, part of the [Siteman Cancer Center DASHboards \(Data and Statistics Hub\)](#).
 - For additional guidance on the needs and priorities of the catchment, please reach out to Dr. Bettina Drake, Associate Director of Community Outreach & Engagement, at drakeb@wustl.edu.
- Must involve at least one SCC satellite site or partner in SCC's catchment area (e.g., Siteman Cancer Network (SCN) site, BJC Collaborative member, Federally Qualified Health Center, or community organization).
 - Questions regarding eligible sites should be directed to Katie Hoey, Program Manager of External Partnerships at hoey@wustl.edu.
- Priority will be given to projects with large accrual targets (>500) and/or involving an SCN partner or BJC Collaborative site.
- Meet the NCI definition of "interventional": *A research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes.*
 - NEW:** A formal letter of support from the Siteman Protocol Development (PD) office indicating that the study has been reviewed and meets the NIH definition of

“interventional” is required at the time of submission. Please reach out to protocoldevelopment@wustl.edu for more information

- PIs are highly encouraged to meet with the [SCC Patient Research Advisory Board](#) (PRAB), or an equivalent group, prior to, or within 2 months of receipt of funding to discuss and obtain feedback related to the study.

C. Eligibility

- Faculty Appointment:** The PI must have a full-time faculty appointment at the Assistant Professor, Associate Professor, or Professor level* WashU (WU).
 - *NEW:** Faculty members at the Instructor level are no longer eligible to submit to SIP RDA. Instructors are encouraged to pursue funding from the [ACS IRG \(American Cancer Society Institutional Research Grant\)](#) and the [Siteman Travel Awards](#).
- Siteman Membership:** The contact PI submitting the application must either a) be an approved Siteman Cancer Center member or b) have submitted an acceptable Siteman Cancer Center membership application by the application deadline.
 - Questions regarding membership should be directed to sitemanmembership@wustl.edu.
- SCC Research Program:** The contact PI may be a member of ANY research program at Siteman Cancer Center
- 5% Minimum Effort:** The contact PI AND Co-PI(s) (if applicable) must each have a minimum of 5% effort dedicated to the project. Any proposed effort lower than 5% should be discussed with SCC administration prior to application submission. Salary does not have to be included in the budget (i.e. may be cost-shared), but the PI and co-PI(s) must have protected time available to dedicate to the SIP RDA project
- Info for Current SIP RDA Awardees:** A faculty member currently funded in the role of contact PI by a SIP RDA is not eligible to submit an application as contact PI unless (1) their current award will end by the scheduled start date or (2) their current award is in a no-cost extension.
- Multiple SIP Submissions per Cycle:** A faculty member may submit only one application as contact PI per cycle unless their prospective project is a MU/WU Pre-R01 project or a submission to the Clinical Trial mechanism AND the science is distinct. A PI is allowed to be a co-investigator, or consultant, on any number of submissions.
- Distinct Science:** Please note that SIP RDA will not fund the same science multiple times. If a faculty member has received SIP funding previously (or any other internal funding from Siteman Cancer Center such as a Catalyst Award), they must clearly demonstrate that the science of the proposed project is new and distinct from the previously funded project(s).

D. Terms of the Award

- The total requested amount for direct costs may not exceed \$100,000
- Total project period may not exceed 2 years
- All awardees will be expected to adhere to progress reporting requirements.
- No funding will be released, and no aspect of the project can begin prior to receipt of appropriate institutional compliance approvals (e.g. PRMS, IRB, IACUC, etc.). Projects without necessary regulatory approvals in place 180 days following receipt of the Notice of Award will be reviewed by SCC leadership. This may result in a change of award terms or forfeiture of funding.
- Additional funding may be considered, at the conclusion of the project period, for promising and scalable trials seeking external funding
- Awardees may request adjustments to their SCC role/responsibilities, percent effort, or award period for personal or family situations including, but not limited to, parental leave, child care, elder care, medical conditions, or a disability.



E. Budget

Expenditures Allowed:

- Salary support for investigators and other relevant faculty collaborators or staff. The current NIH salary cap must be used where applicable. This funding mechanism is designed primarily to support staff, not faculty, effort. While a modest amount of faculty support is allowed and may be supported, faculty effort may be reduced/eliminated when final funding assessments are made
- Research supplies
- Per diem charges for patients if part of a clinical study, not reimbursable by standard payment terms
- Technical assistance
- Graduate student/postdoctoral stipends if relevant to the project with detailed justification
- Domestic/foreign travel necessary to carry out proposed project based on institutional travel policies
- Other expenses such as lab and core fees, pathology, imaging, data analysis, etc.
- Consultant costs
- Publications costs not to exceed \$2,000 across the total project period

Expenditures NOT Allowed:

- Secretarial/administrative personnel salary support
- Office equipment and supplies
- Computer (including software) and equipment maintenance fees
- Tuition
- Travel and/or registration/related fees for conferences and
- Travel not essential to carrying out the proposed research
- Purchasing and binding of periodicals and books
- Dues and membership fees in scientific societies
- Recruiting and relocation expenses
- Administrative or institutional charges for services normally considered overhead (e.g. space rental, utilities, building maintenance)
- Non-medical or personnel services to patients
- Sub-contracts to institutions not affiliated with Siteman Cancer Center and pre-award costs
- EAB/IAB honorarium and meeting expenses
- Budgeting for the purchase of equipment is unallowable without prior approval from SCC administration. Non-office equipment and/or technology with the intent to design, test, or facilitate a new device must be required for completion of the project and must not be reasonably accessible elsewhere on campus. All requests must include a detailed justification.

F. Application Guidelines

- Submission of the Statement of Intent (SOI) form is required and due by 4:00pm CST on the due date listed on Page 1. The SOI form can be accessed via the [SIP RDA website](#) or by [clicking here](#). The SOI is not formally reviewed and approval to submit a full application is automatic; PIs should not expect or anticipate any further correspondence from Siteman Administration following submission of the SOI.
- Use Arial 11 point font for text.
- Use the NIH PHS 398 forms, unless otherwise indicated. Applicants must follow the NIH guidelines when completing the forms included below. NIH forms can be found at: <http://grants.nih.gov/grants/funding/phs398/phs398.html>.
- Applications must include all appropriate sections.
- Combine all documents into one PDF document and submit via email to Katie Hoey (hoey@wustl.edu) by 4 pm CST on September 24, 2026
- Late and/or incomplete applications will not be accepted

G. Application Components

1. **SIP RDA Application Cover Sheet (Updated July 2026)**
 - SCC requires a description of your research project written in plain language. The purpose of the plain language summary is to provide a clear overview of the research in straightforward, non-technical language to be shared with the sponsors, donors, the general public, and the media. Please steer clear of scientific words in your plain language abstract.
 - The Becker Library offers a variety of services and resources to assist applicants with making written materials easier to understand. For more information, visit [the Becker Health Literacy and Communication webpage](#)
2. **Re-submissions only: response to prior SIP RDA critique (1 page maximum)**
 - Resubmissions are encouraged. In these instances, we require a response to prior SIP RDA critiques.
 - It is very important that applicants detail how they have responded to prior critiques. Reviewers will have access to previous critiques and the applicant's response.
3. **Specific Aims and Research Strategy (4 page maximum)**
 - **Specific Aims (1 page maximum)**
 - Describe background, community involvement, and community-prioritized research questions that led to the development of the study
 - Outline and briefly describe the aims of the study
 - **Research Strategy (3 pages maximum)**
 - Start each section with the appropriate section heading – Significance and Approach. Cite published experimental details in the Research Strategy section and provide the full reference in a Bibliography and References Cited section (references section NOT included in the 4-page limit).
 - a. **Significance**
 - i. Explain the importance of the problem or critical barrier to progress in the field that the proposed project addresses.
 - ii. Demonstrate the importance of the problem in Siteman's catchment area.
 - b. **Approach**
 - i. Describe the overall strategy, methodology, and analyses to be used to accomplish the specific aims of the project. Include how the data will be collected, analyzed, and interpreted.
 - ii. Discuss potential problems, alternative strategies, milestones, and benchmarks for success anticipated to achieve the aims.
 - iii. Describe how the study will have an impact on Siteman's catchment area.
4. **Study Timeline (1 page maximum)**
 - Provide a description or diagram describing the general study timeline.
5. **Recruitment & Retention Strategy (1 page maximum)**
 - State your planned enrollment, including demographics. Describe your planned or current recruitment strategies to ensure a representative sample that meets your accrual goals. Please include the number of potential patients seen at Siteman Cancer Center and the partner organization per year and the number of those patients needed to meet your recruitment goals.
 - To obtain the above data, please contact Katie Hoey at hoey@wustl.edu and Courtney Harriss at courtney.harriss@wustl.edu
6. **Collaboration Strategy (limit to 30 lines)**



- Describe how the partner site has been engaged in proposal development, how the partner will be impacted by the research, and the plans for informing the partner and its constituents of research findings, as appropriate
- 7. **Plans for Future Research** (1 page maximum)
 - Discuss how findings will lead to future research (e.g., subsequent trial, external funding) at the completion of this project.
- 8. **NIH Biosketches for All Key Personnel** ([Instructions and Samples](#))
- 9. **Budget Form** ([PHS 398 Form](#) Page 4 and 5)
 - Budget Justification: A detailed budget justification is required. For a list of allowable / unallowable costs, see page 4.
 - Facilities and Administrative (F&A)/Indirect Costs: Do not include indirect costs at time of submission. Based on the funding source, indirect costs may be added post-award.
- 10. **Letter(s) of Support**
 - At least one letter of support from the partner institution.
 - Protocol Development (as noted in section D)

H. Review Process

All applications will be evaluated by a review committee comprised of faculty and community experts. Proposals will be evaluated on whether they would have a major impact in developing, implementing, or disseminating innovative and effective interventions to prevent, reduce, or eliminate cancer disparities and advance health equity across the catchment.

For any questions, please contact:
Katie Hoey, Program Manager, External Partnerships
Email: hoey@wustl.edu



APPENDIX A. SITEMAN CANCER CENTER CATCHMENT AREA & AFFILIATES



SCC Satellite Sites

- Barnes-Jewish West County Hospital
- Barnes-Jewish St. Peters Hospital
- Siteman Cancer Center South County
- Christian Hospital
- Memorial Hospital Shiloh, Illinois

Siteman Cancer Network & BJC Collaborative Sites within SCC Catchment

- BJC Alton Memorial Hospital, Alton, Illinois
- Phelps Health, Rolla, Missouri
- Southern Illinois Healthcare, Carbondale, Illinois
- Memorial Health of Springfield, Illinois
- Blessing Health System of Quincy, Illinois
- Sarah Bush Lincoln Health System of Mattoon, Illinois